Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 7, Issue 3, 2008, Pages 202-203

  Cartwright, Thomas H ^a   Genther, Renee ^a  

^a Ocala Oncology   (United States)

Author keywords

Epidermal growth factor receptor inhibitors; FOLFIRI; FOLFOX; Monoclonal antibodies; Rash

Indexed keywords

ADRENALIN; BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; CIMETIDINE; DIPHENHYDRAMINE; FLUOROURACIL; FOLINIC ACID; HYDROCODONE; HYDROCORTISONE; IRINOTECAN; LORAZEPAM; METAXALONE; METHYLPREDNISOLONE; OXALIPLATIN; OXYCODONE; PANITUMUMAB; SUCCINIC ACID; SULFAMETHOXAZOLE; TAMSULOSIN; TRIMETHOPRIM;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; BONE METASTASIS; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; DRUG WITHDRAWAL; HEART ARREST; HUMAN; HYPOTENSION; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; RASH; RECTUM CARCINOMA; URTICARIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 44449130999     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2008.n.027     Document Type: Article

References (5)

1. Erbitux® (cetuximab) prescribing information. ImClone Systems Inc. and Bristol Myers Squibb; 2007.
2. Vectibix® (panitumumab) prescribing information. Amgen Inc; 2007.
3. Van Cutsem E, Peeters M, Siena S, et al. An open-label, randomized phase III clinical trial of panitumumab plus best supportive care versus best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658-64.
4. O'Neil BH, Allen R, Spigel DR, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007; 25:3644-648.
5. Helbling D, Borner M. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol 2007; 18:963-4.